Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
More information
Work
- Jinjing Fu, Nora Franzen, Eline Aas, J. C. Koen van der Mijn, Pim J. van Leeuwen & Valesca P. Retel (2025) - Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer - Value in Health - doi: 10.1016/j.jval.2025.02.004 - [link]
- Astrid Kramer, Lucas F. van Schaik, Daan van den Broek, , Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Ed Schuuring, Wim H. van Harten, Veerle M.H. Coupé & Valesca P. Retèl (2025) - Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology - PharmacoEconomics - doi: 10.1007/s40273-025-01470-7 - [link]
- M. D. Egeler, E. Boomstra, M. W. Rohaan, N. M.J. Van den Heuvel, I. Fraterman, M. Delfos, L. V. van de Poll-Franse, T. H. Borch, I. M. Svane, J. B.A.G. Haanen, V. P. Retèl & A. H. Boekhout (2025) - “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care - Journal of Cancer Survivorship, 19 (1), 109-120 - doi: 10.1007/s11764-023-01452-8 - [link]
- Danalyn Byng, Michael Schaapveld, Esther H. Lips, Frederieke H. van Duijnhoven, Jelle Wesseling, Wim H. van Harten & Valesca P. Retèl (2024) - An early economic evaluation of active surveillance for low-risk ductal carcinoma <i>in situ</i> - Future Oncology, 20 (40), 3451-3462 - doi: 10.1080/14796694.2024.2421152 - [link]
- Lucas Frederik van Schaik, Ellen Gurumay Engelhardt, Wim Herbert van Harten & Valesca Pavlawna Retèl (2024) - Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives - BMC Cancer, 24 (1) - doi: 10.1186/s12885-024-13167-9 - [link]
- Astrid Kramer, Carmen Rubio-Alarcón, Daan van den Broek, Daan C.L. Vessies, Iris van't Erve, Gerrit A. Meijer, Geraldine R. Vink, Ed Schuuring, Remond J.A. Fijneman, Veerle M.H. Coupé & Valesca P. Retèl (2024) - A scenario-drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology - Molecular Oncology, 18 (11), 2730-2742 - doi: 10.1002/1878-0261.13562 - [link]
- L. F. van Schaik, E. G. Engelhardt, E. A. Wilthagen, N. Steeghs, A. Fernández Coves, M. A. Joore, W. H. van Harten & V. P. Retèl (2024) - Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review - Critical Reviews in Oncology/Hematology, 202 - doi: 10.1016/j.critrevonc.2024.104441 - [link]
- Joost G.E. Verbeek, Leyla Azarang, Luis Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca Retel & Wim Van Harten (2024) - High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers - Acta Oncologica, 63, 701-709 - doi: 10.2340/1651-226X.2024.40276
- Michail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, Etienne Brain, Denis Lacombe, Gabe S. Sonke, Anne Vincent-Salomon, Frederieke Van Duijnhoven, Icro Meattini, Orit Kaidar-Person, Philippe Aftimos, Frederic Lecouvet, Fatima Cardoso, Valesca P. Retèl & David Cameron (2024) - EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe - European Journal of Cancer, 207 - doi: 10.1016/j.ejca.2024.114156 - [link]
- Pien Lof, Neeltje J. van Soolingen, Jurgen M.J. Piek, Johanna W.M. Aarts, Valesca P. Retèl, Maarten Bukman, Carolina H. Smorenburg, Willemien J. van Driel, Frédéric Amant, Johannes W. Trum & Christianne A.R. Lok (2024) - Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective - Gynecologic Oncology, 187, 227-234 - doi: 10.1016/j.ygyno.2024.05.018 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- september 2021
- End date approval
- december 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
